Related Experiment Videos
[Antithrombin III and liver cirrhosis]
A Rodríguez Cuartero1, A Mora Guijosa, J Núñez Carril
1Centro de Investigaciones Médicas Mora Lara, Facultad de Medicina, Universidad de Granada.
Revista Espanola De Enfermedades Digestivas
|January 1, 1991
Summary
Antithrombin III (AT III) levels are significantly lower in patients with hepatic cirrhosis, especially in those with decompensated disease. This reduction may be linked to decreased coagulation factors, potentially explaining the absence of thromboembolic events.
Area of Science:
- Hepatology
- Hematology
- Biochemistry
Background:
- Hepatic cirrhosis is a severe liver disease affecting numerous patients.
- Antithrombin III (AT III) is a crucial protein involved in coagulation.
- The synthesis and role of AT III in liver disease require further elucidation.
Purpose of the Study:
- To investigate Antithrombin III (AT III) levels in patients with hepatic cirrhosis.
- To compare AT III levels between healthy individuals and cirrhotic patients.
- To assess the correlation between AT III levels and the severity of liver disease.
Main Methods:
- Quantitative analysis of Antithrombin III (AT III) concentrations.
- Comparative study involving 37 healthy subjects and 103 hepatic cirrhosis patients.
- Statistical analysis to determine significance between groups.
Main Results:
- Mean AT III concentration was significantly lower in cirrhotic patients (14.9 mg/dl) compared to healthy controls (24.3 mg/dl).
- AT III levels were further reduced in decompensated cirrhosis patients (13.9 mg/dl) versus compensated patients (18.1 mg/dl).
- A significant correlation was observed between decreased AT III levels and the severity of hepatic damage.
Conclusions:
- Antithrombin III (AT III) levels decrease in patients with hepatic cirrhosis.
- The degree of AT III reduction correlates with the severity of liver disease.
- The observed lower AT III levels might contribute to the reduced incidence of thromboembolic phenomena in cirrhotic patients.